stockrowLisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
Lisata Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170,000.00, down 83.0% from fiscal 2024.
- Revenue
- −98.3%
- EPS
- +40.7%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
Follow LSTA
Alert me
Lisata Therapeutics, Inc. (LSTA) EV/Sales
As of 6 November 2026, Lisata Therapeutics, Inc. (LSTA) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −2.3× (December 2022) to 7.0× (February 2015); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | — |
| FY2024 | −0.1× | — |
| FY2015 | 2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 0.2× | (23.92%) |
| Jun 2025 | 0.3× | (70.40%) |
| Mar 2016 | 1.0× | (52.98%) |
| Dec 2015 | 2.1× | (36.42%) |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| LSTA Lisata Therapeutics, Inc. | 0.1× |
| PTN Palatin Technologies, Inc. compare | 0.8× |
| ICU SeaStar Medical Holding Corporation compare | 2.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)